Loader

Pathways

PathWhiz ID Pathway Meta Data

PW064757

Pw064757 View Pathway
metabolic

CDRS

Homo sapiens

PW146938

Pw146938 View Pathway
drug action

Cedazuridine Drug Metabolism Action Pathway

Homo sapiens

PW176937

Pw176937 View Pathway
drug action

Cefaclor Action Pathway

Escherichia coli
Cefaclor is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics.5 It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections. Cefaclor exhibits a bactericidal mode of action. It works by binding to and inhibiting bacterial penicillin-binding proteins (PBPs).5 In Escherichia coli, it has a strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preferential binding to PBPs 2 and 3.5 Upon binding to PBPs, ertapenem inhibits bacterial cell wall synthesis by interfering with the lengthening and strengthening of the peptidoglycan portion of the cell wall, thereby inhibiting cell wall synthesis.

PW144939

Pw144939 View Pathway
drug action

Cefaclor Drug Metabolism Action Pathway

Homo sapiens

PW175991

Pw175991 View Pathway
metabolic

Cefaclor Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Cefaclor are predicted with biotransformer.

PW145228

Pw145228 View Pathway
drug action

Cefadroxil Drug Metabolism Action Pathway

Homo sapiens

PW176936

Pw176936 View Pathway
drug action

Cefalotin Action Pathway

Escherichia coli
Cefalotin is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics.5 It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections. Cefalotin exhibits a bactericidal mode of action. It works by binding to and inhibiting bacterial penicillin-binding proteins (PBPs).5 In Escherichia coli, it has a strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preferential binding to PBPs 2 and 3.5 Upon binding to PBPs, ertapenem inhibits bacterial cell wall synthesis by interfering with the lengthening and strengthening of the peptidoglycan portion of the cell wall, thereby inhibiting cell wall synthesis.

PW144580

Pw144580 View Pathway
drug action

Cefalotin Drug Metabolism Action Pathway

Homo sapiens

PW176959

Pw176959 View Pathway
drug action

Cefamandole Action Pathway

Escherichia coli
Cefamandole is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics.5 It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections. Cefamandole exhibits a bactericidal mode of action. It works by binding to and inhibiting bacterial penicillin-binding proteins (PBPs).5 In Escherichia coli, it has a strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preferential binding to PBPs 2 and 3.5 Upon binding to PBPs, ertapenem inhibits bacterial cell wall synthesis by interfering with the lengthening and strengthening of the peptidoglycan portion of the cell wall, thereby inhibiting cell wall synthesis.

PW145374

Pw145374 View Pathway
drug action

Cefamandole Drug Metabolism Action Pathway

Homo sapiens